SCHEMBL3500435

SCHEMBL3500435

CC(C)(O)C#Cc1ccc2nc(Nc3c(Cl)cc(C(C)(C)O)cc3Cl)c3cc[nH]c(=O)c3c2c1

nearest known ligand 0.68

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 17/20 0.68
EGFR P00533 1/20 0.40
MAP3K14 Q99558 1/20 0.36
TTBK1 Q5TCY1 1/20 0.34
PIKFYVE Q9Y2I7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3501559 0.93 JAK2 (0.66) JAK2EGFRMAP3K14
SCHEMBL3501729 0.89 JAK2 (0.65) JAK2EGFRMAP3K14
SCHEMBL2865739 0.89 JAK2 (0.65) JAK2EGFRMAP3K14
SCHEMBL2869385 0.89 JAK2 (0.65) JAK2EGFR
SCHEMBL3502351 0.89 JAK2 (0.65) JAK2EGFR
SCHEMBL2865698 0.89 JAK2 (0.65) JAK2EGFRMAP3K14
SCHEMBL2871725 0.88 JAK2 (0.62) JAK2EGFRMAP3K14TTBK1PIKFYVE
SCHEMBL13249656 0.87 JAK2 (0.77) JAK2
SCHEMBL2864688 0.86 JAK2 (0.76) JAK2
SCHEMBL1664799 0.86 JAK2 (0.65) JAK2EGFRMAP3K14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349865-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-01-08 US claimed
EP-2200612-B1 INHIBITORS OF JANUS KINASES SCHERING CORP (US) 2012-08-08 EP claimed
US-20100197634-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2010-08-05 US claimed
US-8349865-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-01-08 US disclosed
US-8349865-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-01-08 US disclosed
EP-2200612-B1 INHIBITORS OF JANUS KINASES SCHERING CORP (US) 2012-08-08 EP disclosed
EP-2200612-B1 INHIBITORS OF JANUS KINASES SCHERING CORP (US) 2012-08-08 EP disclosed
US-20100197634-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2010-08-05 US disclosed
US-20100197634-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2010-08-05 US disclosed
WO-2009035575-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197634-A1 INHIBITORS OF JANUS KINASES JAK2, JAK3, JAK1 JAK2 1/4885EGFR 1070/4885MAP3K14 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.